Search research articles
Contact Us
Filters
Showing results (21-30 of 84) with videos related to
Page
of 9
Sort By:
Lymphatics
|
December 12, 2024
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism
Hyunjoo Lee, Shabirul Haque, Rashmi Gupta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 3, 2018
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion
Rashmi Gupta, Xiao J Yan, Jacqueline Barrientos, et al.
Hematology. American Society of Hematology. Education Program
|
November 25, 2003
Biology and treatment of chronic lymphocytic leukemia
Michael J Keating, Nicholas Chiorazzi, Bradley Messmer, et al.
British Journal of Haematology
|
July 14, 2016
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome
Christopher Mason, Steven Savona, Josephine N Rini, et al.
Blood
|
August 9, 2007
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells
Rajendra N Damle, Sonal Temburni, Carlo Calissano, et al.
Leukemia & Lymphoma
|
September 22, 2015
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia
Matt E Kalaycio, O George Negrea, Steven L Allen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 17, 2019
Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins
Rashmi Gupta, Wentian Li, Xiao J Yan, et al.
Blood
|
August 10, 2012
T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients
Rajendra N Damle, Sonal Temburni, Taraneh Banapour, et al.
Leukemia Research
|
July 4, 2024
Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML
Stephanie Boisclair, Edward Zhou, Phyu Naing, et al.
Clinical Immunology (Orlando, Fla.)
|
September 3, 2016
Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status
Katerina Hatzi, Rosa Catera, Carolina Moreno Atanasio, et al.
Page
of 9
Search research articles
Search
Showing results (21-30 of 84) with videos related to
Sort By:
Page
of 9
Lymphatics
|
December 12, 2024
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism
Hyunjoo Lee, Shabirul Haque, Rashmi Gupta, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 3, 2018
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion
Rashmi Gupta, Xiao J Yan, Jacqueline Barrientos, et al.
Hematology. American Society of Hematology. Education Program
|
November 25, 2003
Biology and treatment of chronic lymphocytic leukemia
Michael J Keating, Nicholas Chiorazzi, Bradley Messmer, et al.
British Journal of Haematology
|
July 14, 2016
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome
Christopher Mason, Steven Savona, Josephine N Rini, et al.
Blood
|
August 9, 2007
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells
Rajendra N Damle, Sonal Temburni, Carlo Calissano, et al.
Leukemia & Lymphoma
|
September 22, 2015
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia
Matt E Kalaycio, O George Negrea, Steven L Allen, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 17, 2019
Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins
Rashmi Gupta, Wentian Li, Xiao J Yan, et al.
Blood
|
August 10, 2012
T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients
Rajendra N Damle, Sonal Temburni, Taraneh Banapour, et al.
Leukemia Research
|
July 4, 2024
Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML
Stephanie Boisclair, Edward Zhou, Phyu Naing, et al.
Clinical Immunology (Orlando, Fla.)
|
September 3, 2016
Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status
Katerina Hatzi, Rosa Catera, Carolina Moreno Atanasio, et al.
Page
of 9